Service de Neurochirurgie, Hôpital de Rangueil, CHU Toulouse, Université Paul Sabatier, Toulouse, France.
Acta Neurochir (Wien). 2013 Jul;155(7):1261-9. doi: 10.1007/s00701-013-1732-y. Epub 2013 May 21.
Central neurocytoma (CN) is a rare intraventricular tumour. Surgery has been highly recommended for CN, although it entails a significant chance to harm the patient. We aimed to provide new data that would support surgical decision-making and optimise patient information about outcomes after surgery.
Under the auspices of the French Society of Neurosurgery, we conducted a multi-institutional database search in 23 academic hospitals. In all, we reviewed the relevant clinical and radiological data of 82 patients who were operated on for CN between 1984 and 2008, and had their diagnosis confirmed by central pathological review.
The median follow-up was 61 months (range, 6-96 months). Gross total resection (GTR) was achieved in 48 % of the patients, and subtotal resection (STR) in 52 %. The 5-year overall survival rate was 93.8 % (95 % CI, 93.7-93.9). The 5-year progression-free survival rate was 92.1 % (95 % CI, 91.90-92.2) in patients who underwent GTR, compared with 55.3 % (95 % CI, 55.1-55.5) in patients who had STR (p = 0.01). The overall perioperative complication rate was 66 %. The main causes of postoperative disability were some degree of postoperative paresis and/or aphasia (39 %), memory difficulties (29 %) and temporary hydrocephalus (26 %). GTR was not associated with an increased rate of postoperative complications compared with STR. At last follow-up, Karnofsky Performance Score was at least equal to 80 for 90.6 % of the tested patients.
Our series emphasised that maximal surgical resection of CNs offers favourable benefit-risk ratio. These data are of importance to properly counsel patients regarding expected outcomes, and to plan relevant preoperative and postoperative investigations like language and memory function evaluation.
中枢神经细胞瘤(CN)是一种罕见的脑室肿瘤。尽管手术切除有很大的风险,但它一直被高度推荐用于治疗 CN。我们旨在提供新的数据,以支持手术决策,并优化患者对手术后结果的信息。
在法国神经外科学会的支持下,我们在 23 家学术医院进行了多机构数据库检索。我们回顾了 1984 年至 2008 年间因 CN 接受手术治疗且经中枢病理复查确诊的 82 名患者的相关临床和影像学资料。
中位随访时间为 61 个月(范围,6-96 个月)。48%的患者达到了大体全切除(GTR),52%的患者达到了次全切除(STR)。5 年总生存率为 93.8%(95%CI,93.7-93.9)。GTR 组患者的 5 年无进展生存率为 92.1%(95%CI,91.90-92.2),而 STR 组患者的 5 年无进展生存率为 55.3%(95%CI,55.1-55.5)(p=0.01)。总的围手术期并发症发生率为 66%。术后残疾的主要原因是术后不同程度的瘫痪和/或失语(39%)、记忆困难(29%)和暂时性脑积水(26%)。与 STR 相比,GTR 并不增加术后并发症的发生率。末次随访时,90.6%的患者的 Karnofsky 表现评分至少等于 80 分。
我们的研究强调了最大限度地切除 CN 可以带来有利的风险效益比。这些数据对于正确告知患者预期结果以及计划相关的术前和术后评估(如语言和记忆功能评估)非常重要。